Nyxoah SA Ordinary Shares (NYXH)

Price$3.02

Value ScoreD

Growth ScoreA

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-51.75%

Price vs S&P 500 (4W)-4.58%

VGM Score48.13

Market Capitalization$131.25M

All Metrics

Book Value / Share (Quarterly)$1.33

P/TBV (Annual)4.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)48.11%

Cash Flow / Share (Quarterly)$-1.89

Price vs S&P 500 (YTD)-46.95%

Gross Margin (TTM)63.78%

Net Profit Margin (TTM)-826.34%

EPS (TTM)$-2.76

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-2.76

Revenue Growth (5Y)170.65%

EPS (Annual)$-2.75

ROI (Annual)-98.77%

Gross Margin (Annual)63.13%

Net Profit Margin (5Y Avg)-1491.46%

Cash / Share (Quarterly)$1.30

Revenue Growth QoQ (YoY)346.87%

ROA (Last FY)-76.04%

Revenue Growth TTM (YoY)78.01%

EBITD / Share (TTM)$-2.42

ROE (5Y Avg)-64.85%

Operating Margin (TTM)-734.56%

Cash Flow / Share (Annual)$-1.89

P/B Ratio2.29x

P/B Ratio (Quarterly)3.58x

Net Income / Employee (Annual)$-681,714

EV / Revenue (TTM)15.49x

Net Interest Coverage (TTM)-68.54x

ROA (TTM)-77.58%

EPS Incl Extra (Annual)$-2.75

Current Ratio (Annual)1.25x

Quick Ratio (Quarterly)1.16x

3-Month Avg Trading Volume0.09M

52-Week Price Return-61.49%

Revenue / Employee (TTM)$60,946

Tangible BV / Share (Quarterly)$0.03

P/S Ratio (Annual)11.24x

Asset Turnover (Annual)0.08x

52-Week High$8.87

Operating Margin (5Y Avg)-1461.02%

EPS Excl Extra (Annual)$-2.75

CapEx CAGR (5Y)7.45%

Tangible BV CAGR (5Y)77.76%

26-Week Price Return-35.82%

Quick Ratio (Annual)1.16x

13-Week Price Return-32.11%

Total Debt / Equity (Annual)0.86x

Current Ratio (Quarterly)1.25x

Enterprise Value$145.32M

Revenue / Share Growth (5Y)143.04%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-23.64%

Revenue / Employee (Annual)$75,863

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-888.98%

Cash / Share (Annual)$1.30

3-Month Return Std Dev72.34%

Gross Margin (5Y Avg)63.57%

Net Income / Employee (TTM)$-681,714

ROE (Last FY)-183.36%

Net Interest Coverage (Annual)-29.92x

EPS Basic Excl Extra (Annual)$-2.75

Receivables Turnover (TTM)1.81x

Total Debt / Equity (Quarterly)0.86x

EPS Incl Extra (TTM)$-2.76

Receivables Turnover (Annual)2.21x

ROI (TTM)-96.33%

P/S Ratio (TTM)13.99x

Pretax Margin (5Y Avg)-1406.15%

Revenue / Share (Annual)$0.31

Tangible BV / Share (Annual)$1.96

Price vs S&P 500 (52W)-89.70%

Year-to-Date Return-36.84%

5-Day Price Return10.02%

EPS Normalized (Annual)$-2.75

ROA (5Y Avg)-37.16%

Net Profit Margin (Annual)-899.05%

Month-to-Date Return1.98%

Cash Flow / Share (TTM)$-1.86

EBITD / Share (Annual)$-2.42

Operating Margin (Annual)-833.18%

LT Debt / Equity (Annual)0.36x

ROI (5Y Avg)-44.45%

LT Debt / Equity (Quarterly)0.36x

EPS Basic Excl Extra (TTM)$-2.76

P/TBV (Quarterly)174.75x

P/B Ratio (Annual)3.58x

Inventory Turnover (TTM)0.79x

Pretax Margin (TTM)-810.21%

Book Value / Share (Annual)$1.33

Price vs S&P 500 (13W)-41.85%

Beta1.31x

Revenue / Share (TTM)$0.23

ROE (TTM)-135.30%

52-Week Low$2.30

vGradeD

gGradeA

mGradeF

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.07

About

Nyxoah SA develops and commercializes the Genio system, a CE-Mark validated bilateral neurostimulation therapy for moderate to severe Obstructive Sleep Apnea (OSA). The company addresses a substantial patient population, as OSA is associated with increased mortality risk and serious comorbidities including cardiovascular disease, depression, and stroke. Genio represents a novel treatment approach in a significant market opportunity for sleep-disordered breathing.